NutriStack
Apigenin and NMN, a synergy.
NMN raises NAD+ substrate; apigenin inhibits CD38, the enzyme that consumes NAD+. Combined effect on whole blood NAD+ may be additive.
One pair, every claim cited. The two substances, the type, the mechanism, the recommendation, and the primary literature.
Same shape as the other 1,729 pairs in the public database.
From the interaction database
What the row says.
Every entry follows the same shape: what is happening, the mechanism, the recommendation, and the primary literature.
At a glance
- Pair type
- Synergy
- Evidence (highest tier)
- Emerging
- Source citations
- 1 source
- Stack Score effect
- +2 to your Stack Score (per scored synergy row).
- Scope
- Supplement × Supplement
- Last verified
- May 30, 2026
Synergy · Emerging evidence
Synergy
What is happening. NMN raises NAD+ substrate; apigenin inhibits CD38, the enzyme that consumes NAD+. Combined effect on whole blood NAD+ may be additive.
Mechanism. NMN provides substrate for NAD+ synthesis; apigenin reduces NAD+ consumption by inhibiting CD38. Mechanisms are complementary.
Recommendation. Combine for NAD+ optimization in longevity-focused stacks. Track NAD+ via specialty assays (Jinfiniti, ChromaDex) at baseline and 8 weeks.
Sources (1)
- Escande C et al. Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. 2013
Stack Score
How this pair moves the number.
Effect on the composite score
If both Apigenin and NMN are in the same stack, this pair applies +2 to your Stack Score (per scored synergy row).
The full algorithm, the clamping rules, and four worked stacks are documented at /methodology/stack-score.
Check your full routine
One pair was the worked example. NutriStack runs every pair in your stack at once.
Drop in your supplements and prescriptions and the public database surfaces every interaction, synergy, timing rule, and contraindication, every one linked to its primary source.